Skip to main content
. 2024 Sep 5;76:102820. doi: 10.1016/j.eclinm.2024.102820

Fig. 4.

Fig. 4

The decision curve analyses of XGBoost and the model with the most disputable predictive efficacy apart from XGBoost. Outcomes of all the patients: in-hospital mortality (a), re-admission within 30 days after discharge (b), and mortality within 180 days after discharge (c). XGBoost, eXtreme Gradient Boosting; AdaBoost, Adaptive Boosting.